Promising combo for tough breast cancer hits roadblock: trial ends early
NCT ID NCT04216472
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 25 times
Summary
This study tested a combination of two drugs (nab-paclitaxel and alpelisib) given before surgery to people with a specific type of aggressive breast cancer (triple-negative) that had stopped responding to standard chemotherapy. The goal was to see if the combo could shrink tumors more effectively. Only 6 people enrolled before the trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.